An overview of infectious complications in children on new biologic response-modifying agents

Pediatric Health

Volumn 4, Issue 5, 2010, Pages 509-517

  Abinun, Mario ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

biologic response modifying agents; biologics; children; cytokines; immune dysregulation; infection; inflammation; interleukins; rheumatic disorders; TNF

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CRYOPYRIN; CYCLOSPORIN; ETANERCEPT; GAMMA INTERFERON; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; MERCAPTOPURINE; METHOTREXATE; MYELOID DIFFERENTIATION FACTOR 88; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; TOLL LIKE RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; ASPERGILLOSIS; AUTOIMMUNE HEPATITIS; AUTOINFLAMMATORY DISEASE; B LYMPHOCYTE; BACTERIAL ARTHRITIS; BEHCET DISEASE; CANDIDIASIS; COCCIDIOIDOMYCOSIS; CROHN DISEASE; CYTOKINE RELEASE; DEMYELINATING DISEASE; DRUG SAFETY; GENE MUTATION; GUILLAIN BARRE SYNDROME; HEPATITIS; HEPATITIS B REACTIVATION; HISTOPLASMOSIS; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFECTION RISK; INFECTIOUS COMPLICATION; INFLAMMATION; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; LISTERIOSIS; LUNG GRANULOMA; LUPUS LIKE SYNDROME; LYMPHOCYTE FUNCTION; LYMPHOMA; MENDELIAN SUSCEPTIBILITY TO MYCOBACTERIAL DISEASE; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; NEUTROPENIA; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PANCYTOPENIA; PEDIATRICS; PNEUMOCYSTOSIS; PNEUMONIA; PRIMARY IMMUNODEFICIENCY DISORDER; PYELONEPHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SEPTICEMIA; SIDE EFFECT; T CELL LYMPHOMA; T LYMPHOCYTE; TUBERCULOSIS; VIRUS REACTIVATION;

EID: 78149348141     PISSN: 17455111     EISSN: None     Source Type: Journal    
DOI: 10.2217/phe.10.57     Document Type: Review

References (58)

1. Lee SJ, Chinen J, Kavanaugh A: Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins. J. Allergy Clin. Immunol. 125(Suppl. 2), S314-S323 (2010).
2. Chan AC, Carter PJ: Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10, 301-316 (2010).
3. Dinarello CA: Anti-inflammatory agents: present and future. Cell 140, 935-950 (2010).
4. Ilowite NT: Update on biologics in juvenile idiopathic arthritis. Curr. Opin. Rheumatol. 20(5), 613-618 (2008).
5. Beresford MW, Baildam EM: New advances in the management of juvenile idiopathic arthritis-2: the era of biological. Arch. Dis. Child Educ. Pract. Ed. 94, 151-156 (2009).
6. Breda L, Del Torto M, De Sanctis S, Chiarelli F: Biologics in childrens autoimmune disorders: efficacy and safety. Eur. J. Pediatr. doi:10.1007/s00431- 010- 1238-z. (2010) (Epub ahead of print).
7. Singh JA, Christensen R, Wells GA et al.: Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst. Rev. 4, 1-79 (2009).
8. Raychaudhuri SP, Nguyen CT, Raychaudhuri SK, Gershwin ME: Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun. Rev. 9, 67-81 (2009).
9. Salvana EM, Salata RA: Infectious complications associated with monoclonal antibodies and related small molecules. Clin. Microbiol. Rev. 22, 274-290 (2009).
10. Lovell DJ, Reiff A, Ilowite NT et al.; Pediatric Rheumatology Collaborative Study Group: Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 58(5), 1496-1504 (2008).
11. Giannini EH, Ilowite NT, Lovell DJ et al.; Pediatric Rheumatology Collaborative Study Group: Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 60(9), 2794-2804 (2009).
12. Horneff G, Schmeling H, Biedermann T et al.: The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 63(12), 1638-1644 (2004).
13. Horneff G, De Bock F, Foeldvari I et al.; German and Austrian Paediatric Rheumatology Collaborative Study Group: Safety and efficacy of combination of etanercept and methotrexate compared with treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann. Rheum. Dis. 68(4), 519-525 (2009).
14. Dekker L, Armbrust W, Rademaker CM, Prakken B, Kuis W, Wulffraat NM: Safety of anti-TNFa therapy in children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 22(2), 252-258 (2004).
15. Prince FHM, Twilt M, ten Cate R et al.: Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann. Rheum. Dis. 68, 635-641 (2009).
16. Pain CE, McCann LJ: Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics 3, 127-139 (2009).
17. Burmester GR, Mease P, Dijkmans BA et al.: Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann. Rheum. Dis. 68(12), 1863-1869 (2009).
18. Ruperto N, Lovell DJ, Cuttica R et al.; Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG): Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann. Rheum. Dis. 69(4), 718-722 (2010).
19. Keane J, Gershon S, Wise RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N. Engl. J. Med. 345(15), 1098-1104 (2001).
20. Frank KM, Hogarth K, Miller JL et al.: Investigation of the cause of death in a gene-therapy trial. N. Engl. J. Med. 361, 161.169 (2009).
21. Abinun M, Flood TJ, Cant AJ et al.: Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000.2007). Mol. Immunol. 47(1), 46.51 (2009).
22. Eleftheriou D, Melo M, Marks SD et al.: Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford). 48(8), 978.986 (2009).
23. Marodi L, Casanova JL: Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies? Nat. Rev. Immunol. 10(5), 299.300 (2010).
24. Puel A, Picard C, Lorrot M et al.: Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL.6. J. Immunol. 180(1), 647.654 (2008).
25. Yokota S, Imagawa T, Mori M et al.: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal Phase III trial. Lancet 371(9617), 998.1006 (2008).
26. Cooper N, Davies EG, Thrasher AJ: Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogglobulinaemia requiring replacement intravenous immunoglobulin. Br. J. Haematol. 146(1), 120.122 (2009)
27. Terrier B, Amoura Z, Ravaud P et al.; Club Rhumatismes et Inflammation: Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AIR registry. Arthritis Rheum. doi:10.1002/art. 27541 (2010) (Epub ahead of print).
28. Ruperto N, Lovell DJ, Quartier P et al.; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group: Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 62(6), 1792.1802 (2010).
29. Notarangelo LD, Fischer A, Geha RS et al.; International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies: Primary immunodeficiencies: 2009 update. J. Allergy Clin. Immunol. 124, 1161.1178 (2009).
30. Casanova J-L, Abel L: Primary immunodeficiencies: a field in its infancy. Science 317, 617.619 (2007).
31. Casanova J-L, Fieschi C, Zhang S-Y, Abel L: Revisiting human primary immunodeficiencies. J. Intern. Med. 264, 115.127 (2008).
32. Patel SY, Doffinger R, Barcenas-Morales G, Kumararatne DS: Genetically determined susceptibility to mycobacterial infection. J. Clin. Pathol. 61, 1006.1012 (2008).
33. Filipe-Santos O, Bustamante J, Chapgier A et al.: Inborn errors of IL.12/23- and IFN-g-mediated immunity: molecular, cellular, and clinical features. Sem. Immunol. 18, 347.361 (2006).
34. Bruns H, Meinken C, Schauenberg P et al.: Anti-TNF immunotherapy reduces CD8+ T-cell mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Investig. 119, 1167.1177 (2009).
35. Miller EA, Ernst JD: Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J. Clin. Investig. 119, 1079.1078 (2009).
36. Harris J, Keane J: How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin. Exp. Immunol. 161, 1.9 (2010).
37. Medzhitov R: Recognition of microorganisms and activation of the immune response. Nature 449(7164), 819.826 (2007).
38. Medzhitov R: Inflammation 2010: new adventures of an old flame. Cell 140(6), 771.776 (2010).
39. Schroder K, Tschopp J: The inflammasomes. Cell 140, 821.832 (2010).
40. Doffinger R, Smahi A, Bessia C et al.: X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kB signaling. Nat. Genet. 27(3), 277.285 (2001).
41. Picard C, Puel A, Bonnet M et al.: Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 299(5615), 2076.2079 (2003).
42. von Bernuth H, Picard C, Jin Z et al.: Pyogenic bacterial infections in humans with MyD88 deficiency. Science. 321(5889), 691.696 (2008).
43. von Bernuth H, Puel A, Ku CL et al.: Septicemia without sepsis: inherited disorders of nuclear factor-k B-mediated inflammation. Clin. Infect. Dis. 41 (Suppl. 7), S436.S439 (2005).
44. Masters SL, Simon A, Aksentijevich I, Kastner DL: Horror autoinflammatoricus: The molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621.668 (2009).
45. Kastner DL, Aksentijevich I, Goldbach-Mansky R: Autoinflammatory disease reloaded: a clinical perspective. Cell 140, 784.790 (2010).
46. Henderson C, Gorbach-Mansky R: Monogenic IL.1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. Clin. Immunol. 135, 210.222 (2010).
47. Goldbach-Mansky R, Dailey N J, Canna SW et al.: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1{b} inhibition. N. Engl. J. Med. 355, 581.592 (2006).
48. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al.: (Canakinumab in CAPS Study Group). Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360(23), 2416.2425 (2009).
49. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J: Role of interleukin-1 (IL.1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL.1 blockade. J. Exp. Med. 201, 1479.1486 (2005).
50. Gattorno M, Piccini A, Lasigliè D et al.: The pattern of response to anti.interleuk in-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58(5), 1505.1515 (2008).
51. Ohlsson V, Baildam E, Foster H, Jandial S, Pain C, Strike H, Raman AV: Anakinra treatment for systemic onset juvenile idiopathic arthritis (soJIA). Rheumatology 47, 555-556 (2008).
52. Dinarello CA: Blocking IL-1 in systemic inflammation. J. Exp. Med. 201, 1355-1359 (2005).
53. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A: Malignancy in children and tumor necrosis factor-a blockers: forty-eight cases reported to the food and drug administration. Arthritis Rheum. doi:10.1002/art.27511 (2010) (Epub ahead of print).
54. McCroskery P, Wallace CA, Lovell DJ et al.: Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr. Rheumatol. Online J. 8(1), 18 (2010).
55. Smith MY, Sobel RE, Wallace CA: Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry. Arthritis Care Res. 62, 800-804 (2010).
56. Lepore L, Paloni G, Caorsi R et al.: Follow-up and quality of life of patients with cryopyrinassociated periodic syndromes treated with anakinra. J. Pediatr. doi:10.1016/j. jpeds.2010.02.040. (2010) (Epub ahead of print).
57. Solovic I, Sester M, Gomez-Reino JJ et al.: The risk of tuberculosis related to TNF antagonist therapies: a TBNET consensus statement. Eur. Respir. J. doi: 09031936.00028510v1-erj00285-2010 (2010) (Epub ahead of print).
58. Centers for Disease Control and Prevention: updated guidelines for using interferon g release assays to detect Mycobacterium tuberculosis infection; United States, 2010. MMWR 59(RR-5), 1-25 (2010).